Recombinant TSA56 Antigen for Multi-Genotype Scrub Typhus Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Orientia tsutsugamushi, the causative agent of scrub typhus, fail to provide universal protective immunity across various genotypes and are ineffective in diagnosing different genotypes, leading to frequent severe systemic febrile illnesses and high mortality, especially in Asia-Pacific regions.
Innovation Solution
A recombinant protein antigen derived from conserved sequences of the TSA56 antigen is developed, which is expressed and purified in Escherichia coli, demonstrating reactivity similar to the Boryong TSA56 antigen and inducing humoral immunity, providing protection against multiple genotypes and serving as a diagnostic tool.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccines using TSA56 protein or DNA vaccines are used, then protective immunity is induced for the same genotype, but the vaccine fails to provide protective immunity against other genotypes due to genetic diversity
Solution Approach 1:
The patent applies universality by designing a recombinant protein vaccine that targets conserved epitopes present across multiple tsutsugamushi genotypes. The vaccine composition includes recombinant proteins derived from different genotypes (Karp, Kato, Gilliam, Boryong) that share common antigenic determinants, enabling a single vaccine to provide protective immunity against diverse genotypes rather than being genotype-specific
Solution Approach 2:
The patent applies local quality by focusing on specific conserved regions within the TSA56 protein sequence that are identical or highly similar across different genotypes. Instead of using the entire variable protein sequence, the invention identifies and utilizes localized conserved epitopic regions that maintain structural and functional similarity across genotypes, thereby achieving broad protection through targeted antigen design
2Ease of manufacture
If killed vaccines or recombinant protein vaccines are used, then vaccine development is achieved, but effective protective immunity against multiple genotypes is not induced
Solution Approach 1:
The patent applies composite materials by creating a vaccine composition that combines multiple recombinant proteins from different tsutsugamushi genotypes into a single formulation. This composite approach integrates antigens from Karp, Kato, Gilliam, and Boryong genotypes, each contributing unique but overlapping protective epitopes, thereby achieving both manufacturability and broad protective immunity that neither single-component vaccines nor killed vaccines could provide alone
3Difficulty of detecting and measuring
If serologic diagnosis methods are used, then diagnostic capability is established, but differentiation between genotypes is difficult due to similar clinical symptoms and genetic diversity
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic approach into genotype-specific components. The recombinant proteins from different genotypes (Karp, Kato, Gilliam, Boryong) serve as distinct diagnostic markers that can be used in multiplex assays to identify and differentiate specific genotypes. This segmented diagnostic strategy overcomes the limitation of non-specific serologic tests by providing genotype-resolved detection capability
Data Source
AI summary
The present invention discloses a novel recombinant protein antigen and a vaccine composition using the same, in which the novel recombinant protein antigen is derived from the conserved sequence of a TSA56 antigen and can be useful in the diagnosis of infection with tsutsugamushi and as a vaccine for tsutsugamushi.